These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 17167217)

  • 1. [Pharmacological and clinical profile of solifenacin succinate (Vesicare) developed as a new therapeutic agent for overactive bladder].
    Ohtake A; Sato S; Ikeda K; Sasamata M; Miyata K
    Nihon Yakurigaku Zasshi; 2006 Dec; 128(6):425-32. PubMed ID: 17167217
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents.
    Ohtake A; Saitoh C; Yuyama H; Ukai M; Okutsu H; Noguchi Y; Hatanaka T; Suzuki M; Sato S; Sasamata M; Miyata K
    Biol Pharm Bull; 2007 Jan; 30(1):54-8. PubMed ID: 17202659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially urgency episodes.
    Ohtake A; Sato S; Sasamata M; Miyata K
    J Pharmacol Sci; 2010; 112(2):135-41. PubMed ID: 20134114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms.
    Serels SR; Toglia MR; Forero-Schwanhaeuser S; He W
    Curr Med Res Opin; 2010 Oct; 26(10):2277-85. PubMed ID: 20707767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current pharmacotherapy of overactive bladder in neurological patients].
    Shvarts PG; Vinarov AZ; Kadykov AS; Borodulina IV; Popov SV; Kravchenko MA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(12):152-160. PubMed ID: 25741549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solifenacin succinate (VESIcare): overactive bladder therapy.
    Kosier JH; Combest W; Newton M
    Urol Nurs; 2006 Dec; 26(6):496-7. PubMed ID: 17253085
    [No Abstract]   [Full Text] [Related]  

  • 7. Solifenacin.
    Kreder KJ
    Urol Clin North Am; 2006 Nov; 33(4):483-90, ix. PubMed ID: 17011384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A placebo-controlled, double-blind, randomized trial of single daily dose of anti-muscarinic drug solifenacin succinate in patients with overactive bladder].
    Cardozo L; Lisec M; Milard R; Van Vierssen Trip O; Kuzmin I; Drogendijk TE; Huang AM
    Akush Ginekol (Sofiia); 2007; 46(5):55-7. PubMed ID: 17974184
    [No Abstract]   [Full Text] [Related]  

  • 9. The emerging role of solifenacin in the treatment of overactive bladder.
    Robinson D; Cardozo L
    Expert Opin Investig Drugs; 2004 Oct; 13(10):1339-48. PubMed ID: 15461562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solifenacin: treatment of overactive bladder.
    Chilman-Blair K; Bosch JL
    Drugs Today (Barc); 2004 Apr; 40(4):343-53. PubMed ID: 15190387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The emergence of new drugs for overactive bladder.
    McCrery RJ; Smith PP; Appell RA
    Expert Opin Emerg Drugs; 2006 Mar; 11(1):125-36. PubMed ID: 16503831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urodynamic effects of solifenacin in untreated female patients with symptomatic overactive bladder.
    Tanaka Y; Masumori N; Tsukamoto T
    Int J Urol; 2010 Sep; 17(9):796-800. PubMed ID: 20649825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overactive bladder treatments in early phase clinical trials.
    Colli E; Digesu GA; Olivieri L
    Expert Opin Investig Drugs; 2007 Jul; 16(7):999-1007. PubMed ID: 17594185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder.
    Chapple CR
    Expert Opin Pharmacother; 2006 Dec; 7(17):2421-34. PubMed ID: 17109616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overactive bladder medical management in the elderly: it is time to go beyond the tip of the iceberg.
    Cornu JN
    Eur Urol; 2013 Jul; 64(1):82-3. PubMed ID: 23398768
    [No Abstract]   [Full Text] [Related]  

  • 16. [Pharmacological and clinical profile of imidafenacin developed as a new therapeutic agent for overactive bladder].
    Uno T; Kobayashi F; Ogata A; Konomi T
    Nihon Yakurigaku Zasshi; 2008 May; 131(5):379-87. PubMed ID: 18480570
    [No Abstract]   [Full Text] [Related]  

  • 17. Solifenacin pharmacology.
    Morales-Olivas FJ; Estañ L
    Arch Esp Urol; 2010; 63(1):43-52. PubMed ID: 20157218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of oral solifenacin succinate treatment on intraocular pressure: glaucoma paradox during overactive bladder treatment.
    Sekeroglu MA; Hekimoglu E; Petricli IS; Tasci Y; Dolen I; Arslan U
    Int Urogynecol J; 2014 Nov; 25(11):1479-82. PubMed ID: 24803216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reply from authors re: Jean-Nicolas Cornu. Overactive bladder medical management in the elderly: it is time to go beyond the tip of the iceberg. Eur Urol 2013;64:82-3.
    Wagg A; Dale M; Tretter R; Stow B; Compion G
    Eur Urol; 2013 Jul; 64(1):83-4. PubMed ID: 23465518
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites?
    Michel MC; Hegde SS
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Nov; 374(2):79-85. PubMed ID: 17021853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.